Amifampridine phosphate | CAS# 446254-47-3 |CAS#54-96-6

MedKoo Cat#: 319929 | Name: Amifampridine phosphate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The phosphate salt of amifampridine is a more stable formulation that does not require refrigeration. In the United States, amifampridine is under investigation for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Amifampridine is also used to treat many of the congenital myasthenic syndromes, particularly those with defects in choline acetyltransferase, downstream kinase 7, and those where any kind of defect causes "fast channel" behaviour of the acetylcholine receptor.

Chemical Structure

Amifampridine phosphate

CAS#446254-47-3 (phosphate)

Theoretical Analysis

MedKoo Cat#: 319929

Name: Amifampridine phosphate

CAS#: 446254-47-3 (phosphate)

Chemical Formula: C5H10N3O4P

Exact Mass: 0.0000

Molecular Weight: 207.13

Elemental Analysis: C, 28.99; H, 4.87; N, 20.29; O, 30.90; P, 14.95

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

54-96-6 (free base) 446254-47-3 (phosphate)

Synonym

3,6-DAP; BRN-0110232; BRN 0110232; BRN0110232; NSC 521760; SC10; Amifampridine; Firdapse; Amifampridine phosphate; Zenas

IUPAC/Chemical Name

3,4-Diaminopyridine phosphate

InChi Key

KAICRBBQCRKMPO-UHFFFAOYSA-N

InChi Code

InChI=1S/C5H7N3.H3O4P/c6-4-1-2-8-3-5(4)7;1-5(2,3)4/h1-3H,7H2,(H2,6,8);(H3,1,2,3,4)

SMILES Code

NC1=C(N)C=NC=C1.O=P(O)(O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related: 446254-47-3 (phosphate) 54-96-6 (free base).

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 207.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, Brannagan T, Lavrnić D, Shieh P, Vial C, Meisel A, Komoly S, Schoser B, Sivakumar K, So Y; LEMS Study Group. Amifampridine phosphate (Firdapse®) is Effective and Safe in A Phase 3 Clinical Trial in LEMS. Muscle Nerve. 2016 Feb 6. doi: 10.1002/mus.25070. [Epub ahead of print] PubMed PMID: 26852139. 2: Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M. The European LEMS Registry: Baseline Demographics and Treatment Approaches. Neurol Ther. 2015 Dec;4(2):105-24. doi: 10.1007/s40120-015-0034-0. Epub 2015 Nov 2. PubMed PMID: 26525537; PubMed Central PMCID: PMC4685864. 3: Haroldsen PE, Musson DG, Hanson B, Quartel A, O'Neill CA. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults. Clin Ther. 2015 Jul 1;37(7):1555-63. doi: 10.1016/j.clinthera.2015.05.498. Epub 2015 Jun 20. PubMed PMID: 26101174. 4: Haroldsen PE, Garovoy MR, Musson DG, Zhou H, Tsuruda L, Hanson B, O'Neill CA. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099. doi: 10.1002/prp2.99. Epub 2014 Dec 9. PubMed PMID: 25692017; PubMed Central PMCID: PMC4317230. 5: Dooms M, Pincé H, Simoens S. Do we need authorized orphan drugs when compounded medications are available? J Clin Pharm Ther. 2013 Feb;38(1):1-2. doi: 10.1111/jcpt.12006. Epub 2012 Sep 14. PubMed PMID: 22973866. 6: Sedehizadeh S, Keogh M, Maddison P. The use of aminopyridines in neurological disorders. Clin Neuropharmacol. 2012 Jul-Aug;35(4):191-200. doi: 10.1097/WNF.0b013e31825a68c5. Review. PubMed PMID: 22805230. 7: Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341-9. doi: 10.2147/NDT.S10464. Epub 2011 May 30. PubMed PMID: 21822385; PubMed Central PMCID: PMC3148925. 8: Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther. 2012 Feb;37(1):53-7. doi: 10.1111/j.1365-2710.2011.01249.x. Epub 2011 Apr 19. PubMed PMID: 21501202.